AnaptysBio Inc
NASDAQ:ANAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AnaptysBio Inc
NASDAQ:ANAB
|
US |
|
C
|
Chaintech Technology Corp
TWSE:2425
|
TW |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
US |
|
M
|
Mayfair Gold Corp
XTSX:MFG
|
CA |
|
E
|
Ekipa Holding SA
WSE:EEE
|
PL |
|
F
|
Fintec Global Bhd
KLSE:FINTEC
|
MY |
|
Plexus Holdings PLC
LSE:POS
|
UK |
|
E
|
Ege Profil Ticaret ve Sanayi AS
IST:EGPRO.E
|
TR |
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
ID |
Bankruptcy Probability
AnaptysBio Inc's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
AnaptysBio Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
AnaptysBio Inc
NASDAQ:ANAB
|
1.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
374.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
AnaptysBio Inc's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, AnaptysBio Inc has total debt of 276.5m USD. This includes both short-term (0 USD) and long-term (276.5m USD) debt.
You can find a full breakdown on its Balance Sheet.
